سعر Rani 50mg/2ml 5 amp. for i.v/im injection (cancelled) 2026

Ranitidine 50 mg/2 ml solution for IV/IM injection, 5 ampoules (Pharco, Egypt); listed as cancelled in Egyptian directories.

• Some hospitalised patients with pathological hypersecretory conditions or intractable duodenal ulcers, or short-term alternative to oral dosing in patients unable to take oral medication.DailyMed (US National Library of Medicine)

• Headache (sometimes severe); rarely malaise, dizziness, somnolence, insomnia, vertigo, reversible confusion or hallucinations (mainly in severely ill elderly); constipation, diarrhoea, nausea/vomiting, abdominal pain, rare pancreatitis.International label, same formulation · DailyMed (US National Library of Medicine)
• Rare: hepatitis (discontinue immediately), arrhythmias (tachycardia, bradycardia, AV block), blood count changes including agranulocytosis and aplastic anaemia, rash/erythema multiforme, hypersensitivity reactions including anaphylaxis and angioedema, acute interstitial nephritis, gynaecomastia/galactorrhoea.International label, same formulation · DailyMed (US National Library of Medicine)
• Transient pain at the IM injection site; transient local burning or itching with IV administration.International label, same formulation · DailyMed (US National Library of Medicine)

• Hypersensitivity to ranitidine or any ingredient of the product.International label, same formulation · DailyMed (US National Library of Medicine)

• Symptomatic response does not preclude gastric malignancy.International label, same formulation · DailyMed (US National Library of Medicine)
• Ranitidine is excreted mainly by the kidney: adjust dose in renal impairment; use caution in hepatic dysfunction. Avoid in patients with a history of acute porphyria (may precipitate attacks).International label, same formulation · DailyMed (US National Library of Medicine)
• False-positive urine protein tests with Multistix may occur; sulfosalicylic acid testing is recommended.International label, same formulation · DailyMed (US National Library of Medicine)

• WarfarinAltered prothrombin time reported; monitor closely.DailyMed (US National Library of Medicine)
• ProcainamideHigh ranitidine doses reduce renal excretion of procainamide and N-acetylprocainamide; monitor for toxicity at oral ranitidine doses above 300 mg/day.DailyMed (US National Library of Medicine)
• Ketoconazole, atazanavir, delavirdine, gefitinibAbsorption may be reduced by increased gastric pH (ketoconazole exposure reduced up to 95% at gastric pH >= 6).DailyMed (US National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; animal studies at up to 160 times the human dose showed no fetal harm. Use in pregnancy only if clearly needed.International label, same formulation · DailyMed (US National Library of Medicine)
• Ranitidine is secreted in human milk; use caution in nursing mothers.International label, same formulation · DailyMed (US National Library of Medicine)

• Ranitidine: Competitive, reversible inhibitor of histamine at H2 receptors including those on gastric parietal cells (US Zantac injection label).